Previous studies reported that pharmacological FAK inhibition in immunocompetent genetic PDAC (KPC) [312] or PDA-grafted mouse models [315], decreased tumor-infiltration with immunosuppressive cells, and lengthened animal survival when the FAK inhibitor was combined with immunotherapy [312]. Here, PTK2 is linked to Patent ductus arteriosus.